Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority
As the allergy season is starting, we at TIEFENBACHER PHARMACEUTICALS are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.
We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health! The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada.
Reach out to AET – TIEFENBACHER PHARMACEUTICALS at BePharma, the most important Pharma B2B Event in Latin America from October 10-12!
Alfred E. Tiefenbacher's Pirfenidone Receives Approval in the EMA
Alfred E. Tiefenbacher' Pirfenidone AET
TIEFENBACHER GROUP BECOMES MEMBER OF THE PHARMACEUTICAL SUPPLY CHAIN INITIATIVE (PSCI)
TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for TIEFENBACHER GROUP to become a leading global developer and manufacturer of highly potent drugs for the treatment of cancer and other diseases. It follows our company´s strategy to make medicines more affordable, more available, and better than before.
Four drugs recommended for approval by CHMP at April meeting